Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes

Open-Label, Non-Randomized, Single-Arm, Multicenter Pilot Clinical Trial to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes

FAITH-T1D/1, exploratory, Phase I, open-label, non-randomized, single-arm, multicenter clinical trial designed to evaluate the dose-dependent effects of tirzepatide on gastric emptying in adults with type 1 diabetes (T1D) and overweight or obesity.

The study will investigate tirzepatide administered once weekly as an adjunct to participants' usual insulin therapy delivered through automated insulin delivery (AID) systems. Tirzepatide will be administered subcutaneously, with gradual dose escalation from 2.5 mg up to 15 mg at four-week intervals, according to clinical tolerability and the protocol-defined dosing schedule. Its use in this population is off-label.

The study follows a longitudinal, within-subject design in which each participant serves as their own control. Gastric emptying will be assessed by gastric emptying scintigraphy using a standardized solid meal at baseline and at weeks 4, 8, 16 and 24. The primary objective is to characterize changes in gastric emptying in relation to tirzepatide dose. Secondary and exploratory objectives include evaluating metabolic and glycemic parameters, gastrointestinal symptoms, postprandial glucagon, lipidomic and metabolomic profiles, and the safety and tolerability of treatment. Continuous glucose monitoring and AID system data will also be reviewed throughout the study.

The target is 12 evaluable participants, with a maximum of 14 participants allowed to account for early withdrawals before an evaluable post-baseline assessment. The study includes a screening period, approximately 24 weeks of treatment and follow-up assessments through week 30.

Safety assessments will include treatment-emergent adverse events, gastrointestinal symptoms, hypoglycemia and diabetic ketoacidosis, as well as monitoring of tolerability during dose escalation. An independent Data and Safety Monitoring Committee is planned in accordance with the protocol.

The trial will be conducted at two Spanish hospital centers: Hospital Universitario Ramón y Cajal and Hospital Universitari i Politècnic La Fe. The study is exploratory and mechanistic; it is intended to characterize pharmacodynamic effects, estimate within-subject changes and inform the design of future confirmatory studies, rather than establish definitive clinical efficacy.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

12

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Madrid
      • Madrid, Madrid, Spanien, 28034
        • Rekruttering
        • Hospital Universitario Ramón y Cajal
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Written informed consent: Participants must have received information about the study design, objectives, and potential risks and must provide written informed consent to participate.
  • Ability to comply with study procedures: Ability and willingness to understand the study, comply with the required procedures, and attend all scheduled visits.
  • Age and diagnosis: Age ≥18 years and an established diagnosis of type 1 diabetes mellitus (T1D) for at least 1 year.
  • Stable automated insulin delivery (AID) treatment: Stable treatment with an AID system for at least 90 days before the baseline visit (Visit 0), with a commitment to maintain the same mode of insulin delivery and insulin throughout the study.
  • Baseline HbA1c: HbA1c between 6.3% and 10.5% at baseline.
  • Body mass index and weight stability: BMI ≥25 kg/m², with stable body weight (variation ≤5 kg) during at least the 90 days before inclusion.
  • Contraception requirements: Participants with reproductive potential must agree to use effective contraception throughout the study and for at least 6 months after the end of the study. The protocol specifies a highly effective contraceptive method plus a barrier method for participants with reproductive potential.

Exclusion Criteria:

Glycemic control and diabetes

  1. Two or more episodes requiring hospitalization for poor glycemic control (hyperglycemia or diabetic ketoacidosis [DKA]) during the 180 days before the baseline visit.

  2. One or more episodes of severe hypoglycemia requiring assistance from another person during the 90 days before baseline.

    Diabetes complications

  3. Active proliferative diabetic retinopathy, or a history of ophthalmologic treatment (photocoagulation, intravitreal injections, or vitrectomy) during the previous 6 months, or anticipated need for such treatment during the 6 months after inclusion.

    Recent cardiovascular disease

  4. Cardiovascular events during the 60 days before baseline, including:

    • Acute myocardial infarction.
    • Stroke.
    • Coronary revascularization.
    • Hospitalization for unstable angina.
    • Heart failure. Gastrointestinal disorders and motility
  5. Clinically significant gastrointestinal disorders, including diabetic gastroparesis.

  6. Previous bariatric surgery.

  7. Chronic use of medications that directly affect gastrointestinal motilityRenal function

  8. Estimated glomerular filtration rate (eGFR) below 15 mL/min/1.73 m² at baseline.

    Neoplasms

  9. Active malignancy or malignancy in remission for less than 5 years.

  10. Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).

    Psychiatric disorders

  11. Severe or unstable psychiatric disorders, including uncontrolled major depression, schizophrenia, bipolar disorder, or other severe psychiatric conditions, or severe mood or anxiety disorders during the previous 2 years.

    Concomitant medications

  12. Systemic glucocorticoid use for more than 14 days during the 90 days before baseline, excluding replacement therapy.

  13. Use of weight-loss medications or glucose-lowering medications other than insulin during the 90 days before baseline.

    Hypersensitivity

  14. Hypersensitivity to tirzepatide or any of its excipients.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Tirzepatide

Tirzepatide with dose escalation from 2.5 mg to 15 mg.

Tirzepatide with dose escalation from 2.5 mg to 15 mg.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
To characterize the dose-dependent effect of tirzepatide (2.5-15 mg) on gastric emptying (GE) in adults with type 1 diabetes (T1D) and overweight/obesity, assessed as the within-subject change from baseline using gastric emptying scintigraphy (GES).
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24.
Baseline (Week 0) and Weeks 4, 8, 16, and 24.

Sekundære resultatmål

Resultatmål
Tidsramme
Change from baseline in gastric emptying half-time (t½)
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Change from baseline in the area under the gastric retention curve over 0-4 hours (AUC₀-₄h).
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Change from baseline in gastric retention at 2 hours (%GR-2h).
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Change from baseline in gastric retention at 4 hours (%GR-4h).
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24
Baseline (Week 0) and Weeks 4, 8, 16, and 24
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in tight range (70-140 mg/dL)
Tidsramme: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in range (TIR, 70-180 mg/dL)
Tidsramme: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in hypoglycemia
Tidsramme: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in hyperglycemia
Tidsramme: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including glycemic variability.
Tidsramme: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
Correlation between dose-dependent delays in gastric emptying and improvements in postprandial glucose excursions (TIR, 70-180 mg/dL).
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; postprandial glucose assessed over the 6 hours following the standardized test meal
Baseline (Week 0) and Weeks 4, 8, 16, and 24; postprandial glucose assessed over the 6 hours following the standardized test meal
Changes in insulin requirements, including total daily insulin dose
Tidsramme: Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Changes in insulin requirements, including the ratio of prandial to basal insulin dose.
Tidsramme: Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
Change in HbA1c from baseline to the end of the study.
Tidsramme: Baseline (Week 0) and Week 30 (end-of-study visit).
Baseline (Week 0) and Week 30 (end-of-study visit).
Changes in body weight (kg)
Tidsramme: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes in body mass index (kg/m²)
Tidsramme: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes in waist-to-hip ratio (cm)
Tidsramme: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes in percentage of body fat
Tidsramme: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
Changes from baseline in postprandial glucagon concentrations
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Lipoprotein Cholesterol (mg/dL))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Triglycerides (mg/dL))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Particle Number (nmol/L))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial lipidomic profiles (Particle Diameter (nm))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial metabolomic profiles (Glycoprotein (μmol/L))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Changes from baseline in postprandial metabolomic profiles (LMWM (mmol/L))
Tidsramme: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
Incidence of treatment-emergent adverse events including gastrointestinal symptoms
Tidsramme: From the first dose of tirzepatide through the end-of-study visit (Week 30).
From the first dose of tirzepatide through the end-of-study visit (Week 30).
Incidence of treatment-emergent adverse events including hypoglycemia
Tidsramme: From the first dose of tirzepatide through the end-of-study visit (Week 30).
From the first dose of tirzepatide through the end-of-study visit (Week 30).
Incidence of treatment-emergent adverse events including diabetic ketoacidosis
Tidsramme: From the first dose of tirzepatide through the end-of-study visit (Week 30).
From the first dose of tirzepatide through the end-of-study visit (Week 30).
Tolerability of tirzepatide during dose escalation, assessed by the frequency of dose reductions
Tidsramme: During the 24-week treatment period, through Week 24
During the 24-week treatment period, through Week 24
Tolerability of tirzepatide during dose escalation, assessed by the proportion of participants unable to reach the target dose of 15 mg
Tidsramme: During the 24-week treatment period, through Week 24
During the 24-week treatment period, through Week 24

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. september 2026

Primær færdiggørelse (Anslået)

1. oktober 2028

Studieafslutning (Anslået)

1. oktober 2028

Datoer for studieregistrering

Først indsendt

13. oktober 2026

Først indsendt, der opfyldte QC-kriterier

18. november 2026

Først opslået (Faktiske)

20. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • FAITH-T1D/1
  • 2026-527062-72-00 (Ctis)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .